Sigachi Industries Limited (NSE:SIGACHI)
India · Delayed Price · Currency is INR 36.03
-0.52 (-1.42%)
Aug 5, 2025, 3:30 PM IST
SpringWorks Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2021 |
Operating Revenue | 5,208 | 4,882 | 3,990 | 3,020 | 2,503 | 1,928 | Upgrade |
Other Revenue | 0 | - | 51.5 | - | - | 30.49 | Upgrade |
| 5,208 | 4,882 | 4,041 | 3,020 | 2,503 | 1,958 | Upgrade | |
Revenue Growth (YoY) | 27.03% | 20.82% | 33.79% | 20.68% | 27.83% | 37.21% | Upgrade |
Cost of Revenue | 2,446 | 2,221 | 1,987 | 1,407 | 1,204 | 1,034 | Upgrade |
Gross Profit | 2,762 | 2,661 | 2,054 | 1,614 | 1,299 | 924 | Upgrade |
Selling, General & Admin | 780.35 | 736.18 | 579.3 | 390.55 | 220.1 | 181.16 | Upgrade |
Other Operating Expenses | 950.95 | 925.07 | 655.62 | 635.91 | 548.08 | 324.45 | Upgrade |
Operating Expenses | 1,905 | 1,819 | 1,343 | 1,093 | 797.23 | 528.72 | Upgrade |
Operating Income | 857.1 | 842.1 | 710.88 | 521.19 | 501.4 | 395.28 | Upgrade |
Interest Expense | -125.58 | -124.12 | -52.63 | -30.93 | -6.66 | -7.73 | Upgrade |
Interest & Investment Income | - | - | 38.47 | 32.7 | 6.99 | 0.87 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 24.93 | 33.82 | 18.66 | 0.32 | Upgrade |
Other Non Operating Income (Expenses) | 227.86 | 205.2 | -23.92 | -12 | -5.05 | -3.89 | Upgrade |
EBT Excluding Unusual Items | 959.39 | 923.18 | 697.73 | 544.79 | 515.34 | 384.84 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.65 | - | Upgrade |
Pretax Income | -250.68 | 923.18 | 697.73 | 544.79 | 515.99 | 384.84 | Upgrade |
Income Tax Expense | 182.01 | 218.57 | 125.05 | 109.43 | 115.61 | 82.23 | Upgrade |
Earnings From Continuing Operations | -432.69 | 704.61 | 572.68 | 435.36 | 400.37 | 302.6 | Upgrade |
Minority Interest in Earnings | -6.83 | -8.98 | -0.87 | - | - | - | Upgrade |
Net Income | -439.52 | 695.63 | 571.8 | 435.36 | 400.37 | 302.6 | Upgrade |
Net Income to Common | -439.52 | 695.63 | 571.8 | 435.36 | 400.37 | 302.6 | Upgrade |
Net Income Growth | - | 21.66% | 31.34% | 8.74% | 32.31% | 48.95% | Upgrade |
Shares Outstanding (Basic) | 351 | 338 | 315 | 307 | 259 | 230 | Upgrade |
Shares Outstanding (Diluted) | 351 | 338 | 372 | 307 | 259 | 230 | Upgrade |
Shares Change (YoY) | -11.50% | -9.33% | 21.15% | 18.55% | 12.52% | 200.00% | Upgrade |
EPS (Basic) | -1.25 | 2.06 | 1.81 | 1.42 | 1.54 | 1.31 | Upgrade |
EPS (Diluted) | -1.25 | 2.06 | 1.54 | 1.42 | 1.54 | 1.31 | Upgrade |
EPS Growth | - | 33.77% | 8.74% | -8.27% | 17.59% | -50.34% | Upgrade |
Free Cash Flow | - | -163.98 | -722.97 | -716.99 | -184.8 | 202.67 | Upgrade |
Free Cash Flow Per Share | - | -0.49 | -1.94 | -2.33 | -0.71 | 0.88 | Upgrade |
Dividend Per Share | - | 0.100 | 0.100 | 0.200 | - | - | Upgrade |
Dividend Growth | - | - | -50.00% | - | - | - | Upgrade |
Gross Margin | 53.03% | 54.50% | 50.82% | 53.43% | 51.89% | 47.19% | Upgrade |
Operating Margin | 16.46% | 17.25% | 17.59% | 17.26% | 20.03% | 20.19% | Upgrade |
Profit Margin | -8.44% | 14.25% | 14.15% | 14.41% | 16.00% | 15.45% | Upgrade |
Free Cash Flow Margin | - | -3.36% | -17.89% | -23.74% | -7.38% | 10.35% | Upgrade |
EBITDA | 1,037 | 999.86 | 781.19 | 557.05 | 529.96 | 418 | Upgrade |
EBITDA Margin | 19.91% | 20.48% | 19.33% | 18.44% | 21.17% | 21.35% | Upgrade |
D&A For EBITDA | 179.61 | 157.75 | 70.32 | 35.85 | 28.56 | 22.73 | Upgrade |
EBIT | 857.1 | 842.1 | 710.88 | 521.19 | 501.4 | 395.28 | Upgrade |
EBIT Margin | 16.46% | 17.25% | 17.59% | 17.26% | 20.03% | 20.19% | Upgrade |
Effective Tax Rate | - | 23.68% | 17.92% | 20.09% | 22.41% | 21.37% | Upgrade |
Revenue as Reported | 5,436 | 5,088 | 4,106 | 3,087 | 2,529 | 1,960 | Upgrade |
Updated Jan 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.